Ariga N, Moriya T, Suzuki T, Kimura M, Ohuchi N, Satomi S, Sasano H
Department of Pathology, Tohoku University School of Medicine, Sendai, Japan.
Anticancer Res. 2000 Mar-Apr;20(2B):1101-8.
17 beta-hydroxysteroid dehydrogenases (17 beta-HSDs) are involved in the interconversion of biologically active and inactive sex steroids and are considered to play important roles in the in situ metabolism of estrogen in various estrogen dependent tissues. 17 beta-HSD type 1 catalyzes primarily the reduction of estrone (E1) to estradiol (E2), whereas 17 beta-HSD type 2 catalyzes primarily the oxidation of E2 to E1. However, the possible biological roles of these estrogen metabolizing isozymes in human breast cancer, especially in carcinogenesis of the human breast, have not been examined in detail. Because of the potential roles of estrogens in the early stages of human breast carcinogenesis, we have examined the immunolocalization of 17 beta-HSD type 1 and type 2 isozymes and estrogen receptor alpha(ER alpha) in both normal human breast tissue and in breast cancers, including ductal carcinoma in situ (DCIS), proliferative disease without atypia (PDWA) or fibrocystic disease and atypical ductal hyperplasia (ADH). We also correlated these findings with clinicopathological findings, Ki67 antigen, progesterone receptor (PR), c-erbB-2, and p53. 17 beta-HSD type 2 immunoreactivity was sporadically detected in non-proliferative or Ki67 negative ductal epithelia of normal breast, but rarely in breast carcinoma cells. 17 beta-HSD type 1 immunoreactivity was detected in 12/22 (54.5%) PDWA cases, 8/26 (30.8%) ADH cases, and 25/40 (62.5%) DCIS cases, respectively. 17 beta-HSD type 1 immunoreactivity was not statistically correlated with the age of the patients, Ki67 labeling index (LI), and PR LI, p-53 and c-erbB-2 immunoreactivity. There was no significant correlation between ER alpha LI and 17 beta-HSD type 1 immunoreactivity. There was a positive correlation between ER alpha and Ki67 LI in PDWA, whereas a negative correlation was detected between ER alpha and Ki67 LI in DCIS. There was no correlation between ER alpha and Ki67 LI in ADH. These results suggest that in human breast epithelial cells, development of ADH and DCIS may be associated with the loss and/or deviation of oestrogen dependent regulation of cell proliferation.
17β-羟基类固醇脱氢酶(17β-HSDs)参与生物活性和非活性甾体激素的相互转化,被认为在各种雌激素依赖组织中雌激素的原位代谢中起重要作用。17β-HSD1型主要催化雌酮(E1)还原为雌二醇(E2),而17β-HSD2型主要催化E2氧化为E1。然而,这些雌激素代谢同工酶在人类乳腺癌,尤其是在人类乳腺癌发生中的可能生物学作用尚未得到详细研究。由于雌激素在人类乳腺癌发生早期的潜在作用,我们检测了17β-HSD1型和2型同工酶以及雌激素受体α(ERα)在正常人类乳腺组织和乳腺癌中的免疫定位,包括原位导管癌(DCIS)、无异型增生性疾病(PDWA)或纤维囊性疾病以及非典型导管增生(ADH)。我们还将这些发现与临床病理结果、Ki67抗原、孕激素受体(PR)、c-erbB-2和p53进行了相关性分析。在正常乳腺的非增殖性或Ki67阴性导管上皮中偶尔检测到17β-HSD2型免疫反应性,但在乳腺癌细胞中很少检测到。在PDWA病例中,12/22(54.5%)检测到17β-HSD1型免疫反应性;在ADH病例中,8/26(30.8%)检测到;在DCIS病例中,25/40(62.5%)检测到。17β-HSD1型免疫反应性与患者年龄、Ki67标记指数(LI)、PR LI、p-53和c-erbB-2免疫反应性无统计学相关性。ERα LI与17β-HSD1型免疫反应性之间无显著相关性。在PDWA中,ERα与Ki67 LI呈正相关,而在DCIS中,ERα与Ki67 LI呈负相关。在ADH中,ERα与Ki67 LI无相关性。这些结果表明,在人类乳腺上皮细胞中,ADH和DCIS的发生可能与雌激素依赖的细胞增殖调节的丧失和/或偏差有关。